Dr. Schwaab joins Roswell Park Cancer Institute
Roswell Park Cancer Institute has appointed Thomas Schwaab, MD, PhD, as staff physician and assistant professor of oncology in the departments of urology and immunology. Dr. Schwaab offers laparascopic and robot-assisted surgery to patients with kidney cancer and other genitourinary cancers.
Roswell Park Cancer Institute has appointed Thomas Schwaab, MD, PhD, as staff physician and assistant professor of oncology in the departments of urology and immunology. Dr. Schwaab offers laparascopic and robot-assisted surgery to patients with kidney cancer and other genitourinary cancers.
Dr. Schwaab comes to Roswell Park from the Center for Urologic Care, Concord Hospital, Concord, NH. He also served as an adjunct assistant professor of medicine in the Immunologic Therapy Program, Norris Cotton Cancer Center, Dartmouth Medical School, and an adjunct assistant professor of surgery at the Dartmouth Hitchcock Medical Center, Lebanon, NH.
Dr. Schwaab’s research interests focus on vaccine-based immunotherapy, dendritic cell vaccines, antigen presentation on CD1 molecules, and regulation of T regulatory and T suppressor cells. His clinical research is centered on laparoscopy and robotic surgery.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Dr. Goudelocke outlines stand-up urgency in patients with OAB
April 18th 2024"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
